Abstract
The overexpression of the c-erbB-2 oncogene product has been reported in approximately 20–30% of human ovarian cancers and has been correlated with a poor prognosis in ovarian cancer patients. To investigate the function of p185c-erbB-2 in human ovarian cancer cells, a c-erbB-2-specific single-chain antibody (scFv-5R) was expressed in the c-erbB-2-overexpressing SK-OV-3 cell line using a retroviral expression vector. Eight individual clones expressing the single-chain antibody were isolated. These clones have a prominent retention of the cell surface p185c-erbB-2. In this study we compared the proliferation rate, the anchorage-independent growth, the secretion of matrix metalloproteases and of the urokinase-type plasminogen activator. The clones expressing the c-erbB-2 single-chain antibody, the control cells harbouring the empty vector and the parental SK-OV-3 cells they all had similar proliferation rates in the presence of 10% serum and secreted similar amounts of matrix metalloproteases and of the urokinase-type plasminogen activator. However, the expression of the c-erbB-2 oncogene product offers a strong growth advantage under serum-reduced conditions with 1% serum. In contrast to the parental SK-OV-3 and empty vector control cells, the scFv-5R-expressing clones were not able to grow anchorage-independently. These findings suggest that c-erbB-2 enhances transformation abilities of SK-OV-3 ovarian cancer cells without affecting the secretion of proteases and the proliferation of SK-OV-3 ovarian cancer cells in the presence of high concentrations of serum.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beerli, RR, Graus-Porta, D, Woods-Cook, K, Chen, X, Yarden, Y & Hynes, NE (1995) Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15: 6496–6505.
Berchuck, A, Kamel, A, Whitaker, R, Kerns, B, Olt, G, Kinney, R, Soper, JT, Dodge, R, Clarke-Pearson, DL, Marks, P, McKenzie, S, Yin, S & Bast, RC Jr (1990) Overexpression of her-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091.
Chambers, SK, Gertz, RE, Ivins, CM & Kacinski, BM (1995) The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 75: 1627–1633.
Deshane, J, Cabrera, G, Grim, J, Siegal, GP, Pike, J, Alvarez, RD & Curiel, DT (1995) Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody. Gynecol Oncol 59: 8–14.
Deshane, J, Grim, J, Loechel, S, Siegal, GP, Alvarez, RD & Curiel, DT (1996) Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Ther 3: 89–98.
Deshane, J, Siegal, GP, Alvarez, RD, Wang, MH, Feng, M, Cabrera, G, Liu, T, Kay, M & Curiel, DT (1995) Targeted tumor killing via an intracellular antibody against erbB-2. J Clin Invest 96: 2989–2989.
Fukazawa, H, Mizuno, S & Uehara, Y (1995) A microplate assay for quantitation of anchorage-independent growth of transformed cells. Anal Biochem 228: 83–90.
Giani, C, Casalini, P, Pupa, SM, De Vecchi, R, Ardini, E, Colnaghi, MI, Giordano, A & Menard, S (1998) Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation. Oncogene 17: 425–432.
Graus-Porta, D, Beerli, RR & Hynes, NE (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15: 1182–1191.
Graus-Porta, D, Beerli, RR, Daly, JM & Hynes, NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16: 1647–1655.
Gum, R, Wang, SW, Lengyel, E, Yu, D, Hung, M-C, Juarez, J & Boyd, D (1995) Up-regulation of urokinase-type plasminogen activator by expression by the HER2/neu proto-oncogene. Anticancer Res 15: 1167–1172.
Hudziak, RM, Schlessinger, J & Ullrich, A (1987) Increased expression of the putative growth factor receptor p185H E R2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84: 7159–7163.
Kraus, MH, Issing, W, Miki, T, Popescu, NC & Aaronson, SA (1989) Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197.
Meden, H, Marx, D, Rath, W, Kron, M, Fattahi-Meibodi, A, Hinney, B, Kuhn, W & Schauer, A (1994) Overexpression of the oncogene c-erbB2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45–53.
Noguchi, M, Murakami, M, Bennett, W, Lupu, R, Hui, F, Harris, CC & Gerwin, BL (1993) Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res 53: 2035–2043.
Pear, WS, Nolan, GP, Scott, ML & Baltimore, D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392–8396.
Plowman, GD, Culouscu, J-M, Whitney, GS, Green, JM, Carlton, GW, Foy, L, Neubauer, MG & Shoyab, M (1993) Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746–1750.
Schmalfeldt, B, Kuhn, W, Reuning, U, Pache, L, Dettmar, P, Schmitt, M, Jänicke, F, Höfler, H & Graeff, H (1995) Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55: 3958–3963.
Tamakoshi, K, Kikkawa, F, Nawa, A, Ishikawa, H, Mizuno, K, Tamakoshi, A, Yamagata, S, Suganuma, N & Tomoda, Y (1995) Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 76: 2565–2571.
Tan, M, Yao, J & Yu, D (1997) Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199–1205.
Yamamoto, T, Ikawa, S, Akiyama, T, Semba, K, Nomura, N, Miyajima, N, Saito, T & Toyoshima, K (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature (London) 319: 230–234.
Yu, DH & Hung, M-C (1991) Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6: 1991–1996.
Yu, D, Wolf, JK, Scanlon, M, Price, JE & Hung, M-C (1993) Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891–898.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Wiechen, K., Karaaslan, S., Turzynski, A. et al. Suppression of the c-erbB-2 gene product decreases transformation abilities but not the proliferation and secretion of proteases of SK-OV-3 ovarian cancer cells. Br J Cancer 81, 790–795 (1999). https://doi.org/10.1038/sj.bjc.6690765
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690765
Keywords
This article is cited by
-
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Journal of Ovarian Research (2014)
-
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models
Investigational New Drugs (2012)